Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Clinical trial NCT03602079 · COMPLETED

Trial details

NCT number: NCT03602079
Sponsor: Klus Pharma Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HER2-positive Breast Cancer HER2 Gene Mutation HER-2 Gene Amplification HER2 Positive Gastric Cancer Salivary Gland Cancer Salivary Gland Tumor Salivary Gland Carcinoma Salivary Gland Neoplasms Lung Cancer Colo-rectal Cancer Rare Diseases Solid Tumor

Start date: 2018-07-16
Primary completion: 2022-01-12
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.